NCT06665594 Effect of TXA on Reducing Bruising After Filler Injection
| NCT ID | NCT06665594 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Wisconsin, Madison |
| Condition | Facial Filler Injections |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-12-05 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2025-12-05 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is: * Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection? Participants will receive the study medication along with the standard facial filler injection and complete surveys.
Eligibility Criteria
Inclusion Criteria: * Age equal to or greater than 18 but less than or equal to 89 years. * Participants interested in facial filler (HA) injection. * English speaking. Exclusion Criteria: * Minors or under the age of 18 * Participant over the age of 89 * Pregnant or breast-feeding women * Individuals unable to give consent due to another condition such as impaired decision-making capacity. * Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis * Participants undergoing unilateral facial filler (HA) injection * Participants with history of hypersensitivity to TXA or any of the other ingredients * Participants that are on current therapeutic anticoagulation therapy and aspirin use * Participants with stage 2 or greater renal failure * Participants on hemodialysis or peritoneal dialysis * History of diabetes or seizures * Current tobacco smokers * Acquired defective color vision
Contact & Investigator
Daniel Cho, MD, PhD
PRINCIPAL INVESTIGATOR
University of Wisconsin, Madison
Frequently Asked Questions
Who can join the NCT06665594 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Facial Filler Injections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06665594 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06665594 currently recruiting?
Yes, NCT06665594 is actively recruiting participants. Contact the research team at edalatpour@wisc.edu for enrollment information.
Where is the NCT06665594 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT06665594 clinical trial?
NCT06665594 is sponsored by University of Wisconsin, Madison. The principal investigator is Daniel Cho, MD, PhD at University of Wisconsin, Madison. The trial plans to enroll 40 participants.